Synopsis

In this study, we compared a non-opioid pharmacologic pain management regimen to a regimen allowing for breakthrough opioids as needed in the postoperative management of patients who underwent elective uncomplicated arthroscopic knee surgery. The non-opioid pain management protocol consisted of oral acetaminophen 650mg q4h x 3 days, gabapentin 300mg TID x 14 days, ketorolac 10mg q6-8h x 5 days, topical lidocaine patch (4%) 1 patch/day x 14 days, and no breakthrough opioids. At two weeks and 6 weeks postoperatively, there were no significant differences in pain scores between the two groups, suggesting non-inferiority of the non-opioid pain management regimen to the traditional approach of postoperative opioid prescription.

Disclosures

Nothing to Disclose by any Author

Synopsis

Trial leads are used to evaluate response to neuromodulation therapies prior to a definitive implantation. After the trial period, currently available leads require removal and replacement with a permanent lead. However, successful trial periods do not necessarily predict the long term success of a permanent implant 1,2. To reduce the burden of transitioning from a trial lead to a permanent lead, we developed a fully needle-implanted helical wire structure electrode which facilitates a trial period, which may be followed by a straightforward conversion to chronic therapy through either: 1) electrode-augmented transcutaneous stimulation, or 2) attachment to implanted pulse generators as demonstrated in a rodent sciatic nerve model.

Disclosures

This project is supported by Neuronoff Inc., NIH 1U18EB029251-01 Grant, and the DARPA EEI program. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily
endorsed by the Department of Defense or the National Institutes of Health. DL, SK, DV, JW, KG, AH, KAL, SN, MF, and AS are employed by and/or own equity in Neuronoff, Inc.

Synopsis

COVID-19 vaccine related neurological complications which were commonly noted were encephalopathy, acute ischemic stroke, venous thromboembolism, encephalitis, meningitis, acute inflammatory demyelinating neuropathy and olfactory neuropathy. This is an unusual presentation of severe chest wall and upper abdominal pain, progressive weakness, falls in 3-4 weeks. Patient had no pain relief from thoracic epidural or intercostal nerve block and no stimulation or pain relief with spinal cord stimulator trial. Patient could not stand or walk and needed wheelchair and assistance 4 weeks after the second dose of vaccine.

Disclosures

Nothing to disclose by any author.

Synopsis

Results suggest that INP104 may be an effective and well-tolerated acute therapy for migraine in patients who are concurrently using preventive therapies.

Disclosures

Jihan Grant participated in an Advisory Board meeting for Satsuma Pharmaceuticals. Robert Vann, Christopher Fitzpatrick, TinaMarie Lieu, Stephen B. Shrewsbury, and Sheena K. Aurora are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals.

Synopsis

Results suggest that INP104 may be an effective acute treatment option for migraine regardless of prior acute treatment, which includes triptans.

Disclosures

Tanya R. Bilchik has participated in speaker bureaus for AbbVie, Amgen/Allergan, Biohaven Pharmaceuticals, Eli Lilly, Impel Pharmaceuticals, and Teva Pharmaceuticals. Robert Vann, Sutapa Ray, Stephen B. Shrewsbury, and Sheena K. Aurora are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals.

Synopsis

A 49-year-old woman with a history of herpes zoster presented with recurrent left lateral flank pain of one year duration. She was diagnosed with post-herpetic neuralgia. After failing conservative therapy and previous intercostal blocks, she underwent a successful left serratus anterior plane block (SAPB) under ultrasound guidance with over 50% maximal pain relief. Although previous studies have shown efficacy of SAPB, our case uses a unique inferior approach beneath the 8th rib in a patient with much longer duration of symptoms. The SAPB is a feasible alternative intervention for patients with recurrent, intractable post-herpetic neuralgic pain.

Disclosures

Nothing to disclose by any author.

Synopsis

Headache is a common problem worldwide. It can be due to benign or serious conditions. Most of the time the original causes are benign, but it can be disabling that can affect the daily living of individuals and the productivity of community. It is important to know the current prevalence of headaches and the factors that can affect them which can be the leading tool for better assessment and management.

Disclosures

Nothing to disclose by the author.